Article Text

Download PDFPDF
Atorvastatin at 80 mg/day reduced cerebrovascular events more than atorvastatin at 10 mg/day in stable coronary heart disease

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with stable coronary heart disease (CHD), is intensive atorvastatin therapy more effective than moderate atorvastatin therapy for reducing cerebrovascular events?

Clinical impact ratings IM/Ambulatory care ★★★★★★☆ Cardiology ★★★★★★☆ Neurology ★★★★★★☆ Endocrine ★★★★★★☆


Embedded ImageDesign:

randomised controlled trial.

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded (clinicians, patients, and endpoints adjudication committee).*

Embedded ImageFollow up period:

median 4.9 years.

Embedded ImageSetting:

256 sites in 14 countries across 4 continents.

Embedded ImagePatients:

10 001 patients 35–75 years of age (mean age 61 y, 81% men) who had clinically evident CHD (defined as previous myocardial infarction or coronary revascularisation, or previous or current angina with objective evidence of CHD), low density lipoprotein cholesterol (LDL-C) concentration 130–250mg/dl (3.4–6.5 mmol/l), and triglyceride concentration ⩽600 mg/dl (6.8 mmol/l). LDL-C concentration was required to be <130 mg/dl (3.4 mmol/l) during an 8 week run in period with atorvastatin, 10 mg/day.

Embedded ImageIntervention:

atorvastatin, 80 mg/day (n = 4995) …

View Full Text


  • * See glossary.

  • Information provided by author.

  • For correspondence: Dr D Waters, University of California, San Francisco, San Francisco, CA, USA. dwaters{at}

  • Source of funding: Pfizer.

Linked Articles

  • Other articles noted
    BMJ Publishing Group Ltd
  • Glossary
    BMJ Publishing Group Ltd